A New Sunscreen Ingredient Reaches U.S. Shelves After a Long FDA Review

Bemotrizinol is the first new U.S. sunscreen active ingredient in more than two decades, arriving as skin-cancer prevention remains a public health priority.
U.S. health officials move toward wider access to controversial peptide injections

The Trump administration is advancing a policy that could make certain unapproved peptide injections easier to compound, even as FDA materials continue to flag safety and quality concerns.
FDA maps out next wave of AI oversight for medical devices

The FDA’s new fiscal 2027 guidance list shows that artificial intelligence will remain a major focus, with planned documents on AI-enabled device software, generative AI, and related evidence standards.
Americans Worry AI Is Moving Faster Than Safeguards in Health Care

A new AP-NORC poll finds broad concern that artificial intelligence is advancing too quickly, a worry that carries special weight as AI tools expand in medicine and public health.
FDA Peptide Review Could Ease Access, but Safety Questions Remain

Federal advisers have opened the door to temporary access for several unapproved peptide products, even as FDA warnings continue to stress that compounded versions are not reviewed for safety, effectiveness or quality.
FDA mifepristone review stretches into 2027 as debate continues

The FDA says its ongoing safety review of mifepristone will continue into next year, keeping one of the nation’s most closely watched drug-policy fights in motion.
FDA review of abortion pill safety will stretch into 2027

The FDA says its safety review of mifepristone will continue into next year, keeping attention on a drug that is widely used for abortion and miscarriage care.
FDA Links Cyclospora Outbreak to Mexican Lettuce Farm

Federal investigators say they found Cyclospora at a Mexican farm tied to a 2026 lettuce outbreak, adding clarity to a food safety probe that matters for older adults.